#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4276	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2102	585.9	0	.	n	.	0	A662G	SNP	662	662	A	924	924	G	580	G,A	486,4	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4276	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2102	585.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1712	1712	T	632	T,C	567,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4276	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2102	585.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1446	1446	C	639	C,A	556,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6984	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3862	542.3	0	.	n	.	0	G262A	SNP	262	262	G	753	753	A	632	A	568	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6984	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3862	542.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1828	1828	A	567	A	510	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6984	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3862	542.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2462	2462	C	624	C,T	545,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6984	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3862	542.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2536	2536	A	663	A,C	569,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6984	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3862	542.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3088	3088	C	630	C,T	536,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	618	folP	852	852	99.77	folP.l15.c4.ctg.1	1905	97.4	0	.	p	.	0	S68P	NONSYN	202	204	TCG	715	717	CCG	150;151;151	C,T;C;G	129,2;132;132	.	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	618	folP	852	852	99.77	folP.l15.c4.ctg.1	1905	97.4	0	.	p	.	0	A204V	NONSYN	610	612	GCA	1123	1125	GTA	128;128;128	G;T;A	105;105;106	.	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	618	folP	852	852	99.77	folP.l15.c4.ctg.1	1905	97.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1195	1197	AGC	129;130;131	A,C;G;C	105,1;109;111	folP.WHO_G_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1398	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3704	113.2	1	SNP	p	S91F	0	.	.	271	273	TCC	762	764	TCC	118;118;118	T;C;C	101;102;107	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1398	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3704	113.2	1	SNP	p	D95N	0	.	.	283	285	GAC	774	776	GAC	116;114;114	G;A,C;C	104;102,1;102	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1398	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3704	113.2	1	SNP	p	D95G	0	.	.	283	285	GAC	774	776	GAC	116;114;114	G;A,C;C	104;102,1;102	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	27	580	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1686	103.2	1	SNP	p	G45D	0	.	.	133	135	GGC	644	646	GGC	163;163;163	G;G;C	136;134;134	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	360	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1213	89.1	0	.	n	.	0	.206T	INS	206	206	T	677	677	T	157	T	138	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1468	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3290	133.8	0	.	p	.	0	G459S	NONSYN	1375	1377	GGT	1891	1893	AGT	180;181;181	A,G;G;T	158,1;160;157	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1468	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3290	133.8	1	SNP	p	D86N	0	.	.	256	258	GAC	772	774	GAC	172;172;173	G;A,G;C	145;144,1;144	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1468	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3290	133.8	1	SNP	p	S87R	0	.	.	259	261	AGT	775	777	AGT	174;175;175	A,C;G;T,A	142,1;148;145,1	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1468	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3290	133.8	1	SNP	p	S87W	0	.	.	259	261	AGT	775	777	AGT	174;175;175	A,C;G;T,A	142,1;148;145,1	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1468	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3290	133.8	1	SNP	p	S87I	0	.	.	259	261	AGT	775	777	AGT	174;175;175	A,C;G;T,A	142,1;148;145,1	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1468	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3290	133.8	1	SNP	p	S88P	0	.	.	262	264	TCC	778	780	TCC	174;174;173	T;C,G;C	144;145,1;147	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1160	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2913	119.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1633	1635	GGC	151;151;150	G;G;C,A	134;132;128,2	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	1124	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2775	121.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1434	1436	GCA	161;161;163	G;C;A	144;145;145	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1124	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2775	121.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1437	1439	ATC	165;165;163	A;T,C;C	147;142,1;142	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1124	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2775	121.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1449	1451	GTG	166;166;166	G;T;G	147;141;145	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1124	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2775	121.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1449	1451	GTG	166;166;166	G;T;G	147;141;145	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1124	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2775	121.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1953	1955	ACC	152;152;152	A,T;C;C	129,1;136;137	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1124	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2775	121.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2007	2009	GCG	153;154;155	G;C,G;G,T	125;117,3;116,1	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1124	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2775	121.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2007	2009	GCG	153;154;155	G;C,G;G,T	125;117,3;116,1	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1124	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2775	121.3	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2130	2132	GGT	141;139;135	G,C;G;T	119,1;119;114	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1124	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2775	121.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2139	2141	GGC	136;136;135	G;G;C	115;120;116	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1124	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2775	121.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2157	2159	CCG	137;137;138	C;C;G,A	114;119;120,1	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1462	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3329	131.6	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1720	1722	CTG	137;137;136	C;T;G	112;116;114	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	630	porA	1146	1146	99.56	porA.l15.c4.ctg.1	2116	89.4	0	.	p	.	0	S22G	NONSYN	64	66	AGC	560	562	GGC	117;117;117	G;G;C	102;103;101	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	630	porA	1146	1146	99.56	porA.l15.c4.ctg.1	2116	89.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	742	742	C	108	C	99	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	T18M	NONSYN	52	54	ACG	555	557	ATG	186;186;186	A;T,C;G	147;145,1;146	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	T26A	NONSYN	76	78	ACC	579	581	GCC	175;173;174	G;C,T;C	144;144,1;146	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	K41D	NONSYN	121	123	AAA	624	626	GAC	184;184;184	G;A;C,A	151;150;151,1	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	G140R	NONSYN	418	420	GGA	921	923	AGA	168;169;170	A,C;G;A	139,1;142;141	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	930	932	CAA	170;168;168	C,T;A;A	142,1;144;143	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	I209M	NONSYN	625	627	ATC	1128	1130	ATG	160;160;160	A;T;G	142;140;141	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	E210G	NONSYN	628	630	GAA	1131	1133	GGA	161;162;163	G;G;A	140;140;140	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	Q213P	NONSYN	637	639	CAG	1140	1142	CCA	171;171;172	C;C;A	149;150;151	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	S216I	NONSYN	646	648	AGC	1149	1151	ATC	172;173;174	A;T;C	150;145;151	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1260	1262	CAA	159;160;161	C;A;A	142;143;144	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	.	INDELS	760	762	ACA	1264	1268	ATCAA	158;158;158;158;157	A;T;C;A;A	139;141;142;142;141	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	.	INDELS	763	764	TG	1271	1273	AGT	155;154;153	A;G;T	140;138;137	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1278	1280	GAT	155;155;155	G;A,T;T	136;139,1;138	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	D293N	NONSYN	877	879	GAT	1386	1388	AAT	168;168;168	A;A;T	133;132;130	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1392	1394	GAC	169;169;168	G;A;C	131;133;132	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	818	porB1b	1041	1041	96.75	porB1b.l15.c4.ctg.1	1874	129.9	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1395	1397	TAC	168;168;169	T;A;C	132;131;132	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2724	rpoB	4179	4179	100.0	rpoB.l6.c17.ctg.1	5146	158.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2166	2168	CAT	163;162;162	C;A;T	145;142;143	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	462	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	1243	111.3	1	SNP	p	V57M	1	.	.	169	171	ATG	631	633	ATG	189;189;186	A;T;G	161;163;159	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
